Mechanisms of Thrombospondin-1-Mediated Metastasis and Angiogenesis

 

 Buy Article Permissions and Reprints

The major route of tumor spread is through the bloodstream. Once in circulation, the tumor cells aggregate in clumps with platelets, which enhances the tumor cell survival. The tumor emboli will then adhere to the endothelium and by the release of proteases extravasation of the cells will occur. One of the platelet-secreted proteins is thrombospondin-1. In this article, thrombospondin-1 will be described as a modulator of angiogenesis through its role in regulating endothelial cell apoptosis, protease expression, and vascular endothelial growth factor expression. We hope to convey the idea that activity of thrombospondin-1 in tumor progression is dependent upon its interaction with several host- and tumor-associated proteins.

REFERENCES

• 1 Recamier J C. L'Histoire de la Même Maladie. Vol 2 Paris; Gabon 1829: 731-737
  Google Scholar
• 2 Paget S. The distribution of secondary growths in cancer of the breast.  Lancet. 1889;  1 571-573
  PubMedGoogle Scholar
• 3 Billroth T. Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitioners. London; New Syndenham Society 1878: 355
  Google Scholar
• 4 Trousseau A. Clinique Médicale de L'Hôtel de Paris. Vol 3 Paris; Balliere 1865: 654-656
  Google Scholar
• 5 Bick R L. Coagulation abnormalities in malignancy: a review.  Semin Thromb Hemost. 1992;  18 353-372
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Falanga A, Gordon S G. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.  Biochemistry. 1985;  24 5558-5567
  CrossrefPubMedGoogle Scholar
• 7 Tohgo A, Tanaka N, Ashida S, Ogawa H. Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms.  Invasion Metastasis. 1984;  4 134-145
  PubMedGoogle Scholar
• 8 Gasic G J, Gasic T B, Stewart C C. Antimetastatic effects associated with platelet reduction.  Proc Natl Acad Sci USA. 1968;  61 46-52
  PubMedGoogle Scholar
• 9 Karpatkin S, Pearlstein E, Ambrogio C, Coller B S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo.  J Clin Invest. 1988;  81 1012-1019
  CrossrefPubMedGoogle Scholar
• 10 Honn K V, Tang D G, Chen Y Q. Platelets and cancer metastasis: more than an epiphenomenon.  Semin Thromb Hemost. 1992;  18 392-415
  PubMedGoogle Scholar
• 11 Honn K V, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent.  Science. 1981;  212 1270-1272
  PubMedGoogle Scholar
• 12 Marnett L J. Aspirin and the potential role of prostaglandins in colon cancer.  Cancer Res. 1992;  52 5575-5589
  PubMedGoogle Scholar
• 13 Tuszynski G P, Gasic T B, Rothman V L, Knudsen K A, Gasic G J. Thrombospondin, a potentiator of tumor cell metastasis.  Cancer Res. 1987;  47 4130-4133
  PubMedGoogle Scholar
• 14 Tuszynski G P, Rothman V L, Murphy A, Siegler K, Knudsen K A. Thrombospondin promotes platelet aggregation.  Blood. 1988;  72 109-115
  PubMedGoogle Scholar
• 15 Hogg P J, Stenflo J, Mosher D F. Thrombospondin is a slow tight-binding inhibitor of plasmin.  Biochemistry. 1992;  31 265-269
  CrossrefPubMedGoogle Scholar
• 16 Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth.  J Cell Mol Med. 2002;  6 1-12
  PubMedGoogle Scholar
• 17 Baenziger N L, Brodie G N, Majerus P W. A thrombin-sensitive protein of human platelet membranes.  Proc Natl Acad Sci USA. 1971;  68 240-243
  PubMedGoogle Scholar
• 18 DiPietro L A, Polverini P J. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1.  Am J Pathol. 1993;  143 678-684
  PubMedGoogle Scholar
• 19 Reed M J, Puolakkainen P, Lane T F, Dickerson D, Bornstein P, Sage E H. Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization.  J Histochem Cytochem. 1993;  41 1467-1477
  PubMedGoogle Scholar
• 20 Adolph K W. A thrombospondin homologue in Drosophila melanogaster: cDNA and protein structure.  Gene. 2001;  269 177-184
  CrossrefPubMedGoogle Scholar
• 21 Tolsma S S, Volpert O V, Good D J, Frazier W A, Polverini P J, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity.  J Cell Biol. 1993;  122 497-511
  CrossrefPubMedGoogle Scholar
• 22 Dawson D W, Volpert O V, Pearce S F et al.. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.  Mol Pharmacol. 1999;  55 332-338
  PubMedGoogle Scholar
• 23 Reiher F K, Volpert O V, Jimenez B et al.. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.  Int J Cancer. 2002;  98 682-689
  CrossrefPubMedGoogle Scholar
• 24 Iruela-Arispe M L, Lombardo M, Krutzsch H C, Lawler J, Roberts D D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.  Circulation. 1999;  100 1423-1431
  PubMedGoogle Scholar
• 25 Kanda S, Shono T, Tomasini-Johansson B, Klint P, Saito Y. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis.  Exp Cell Res. 1999;  252 262-272
  CrossrefPubMedGoogle Scholar
• 26 Taraboletti G, Morbidelli L, Donnini S et al.. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells.  FASEB J. 2000;  14 1674-1676
  PubMedGoogle Scholar
• 27 Ferrari do Outeiro-Bernstein M A, Nunes S S, Andrade A C, Alves T R, Legrand C, Morandi V. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan.  Matrix Biol. 2002;  21 311-324
  CrossrefPubMedGoogle Scholar
• 28 Guo N, Krutzsch H C, Inman J K, Roberts D D. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells.  Cancer Res. 1997;  57 1735-1742
  PubMedGoogle Scholar
• 29 Dawson D W, Pearce S F, Zhong R, Silverstein R L, Frazier W A, Bouck N P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells.  J Cell Biol. 1997;  138 707-717
  CrossrefPubMedGoogle Scholar
• 30 Jimenez B, Volpert O V, Crawford S E, Febbraio M, Silverstein R L, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.  Nat Med. 2000;  6 41-48
  PubMedGoogle Scholar
• 31 Jimenez B, Volpert O V, Reiher F et al.. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.  Oncogene. 2001;  20 3443-3448
  CrossrefPubMedGoogle Scholar
• 32 Volpert O V, Zaichuk T, Zhou W et al.. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.  Nat Med. 2002;  8 349-357
  PubMedGoogle Scholar
• 33 Freyberg M A, Kaiser D, Graf R, Vischer P, Friedl P. Integrin-associated protein and thrombospondin-1 as endothelial mechanosensitive death mediators.  Biochem Biophys Res Commun. 2000;  271 584-588
  CrossrefPubMedGoogle Scholar
• 34 Freyberg M A, Kaiser D, Graf R, Buttenbender J, Friedl P. Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein.  Biochem Biophys Res Commun. 2001;  286 141-149
  CrossrefPubMedGoogle Scholar
• 35 Stromblad S, Becker J C, Yebra M, Brooks P C, Cheresh D A. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis.  J Clin Invest. 1996;  98 426-433
  PubMedGoogle Scholar
• 36 Hogg P J. Thrombospondin 1 as an enzyme inhibitor.  Thromb Haemost. 1994;  72 787-792
  PubMedGoogle Scholar
• 37 Albo D, Arnoletti J P, Castiglioni A et al.. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.  Biochem Biophys Res Commun. 1994;  203 857-865
  CrossrefPubMedGoogle Scholar
• 38 Arnoletti J P, Albo D, Granick M S et al.. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.  Cancer. 1995;  76 998-1005
  PubMedGoogle Scholar
• 39 Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.  Bioessays. 1993;  15 105-111
  CrossrefPubMedGoogle Scholar
• 40 Albo D, Berger D H, Wang T N, Hu X, Rothman V, Tuszynski G P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system.  Surgery. 1997;  122 493-449 , discussion 499-500
  CrossrefPubMedGoogle Scholar
• 41 Albo D, Berger D H, Tuszynski G P. The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.  J Surg Res. 1998;  76 86-90
  CrossrefPubMedGoogle Scholar
• 42 Albo D, Rothman V L, Roberts D D, Tuszynski G P. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.  Br J Cancer. 2000;  83 298-306
  CrossrefPubMedGoogle Scholar
• 43 John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.  Pathol Oncol Res. 2001;  7 14-23
  PubMedGoogle Scholar
• 44 Qian X, Wang T N, Rothman V L, Nicosia R F, Tuszynski G P. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells.  Exp Cell Res. 1997;  235 403-412
  CrossrefPubMedGoogle Scholar
• 45 Bein K, Simons M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity.  J Biol Chem. 2000;  275 32167-32173
  CrossrefPubMedGoogle Scholar
• 46 Rodriguez-Manzaneque J C, Lane T F, Ortega M A, Hynes R O, Lawler J, Iruela-Arispe M L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.  Proc Natl Acad Sci USA. 2001;  98 12485-12490
  CrossrefPubMedGoogle Scholar
• 47 Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.  Am J Pathol. 1995;  146 1029-1039
  PubMedGoogle Scholar
• 48 Kawahara N, Ono M, Taguchi K et al.. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.  Hepatology. 1998;  28 1512-1517
  CrossrefPubMedGoogle Scholar
• 49 de Fraipont F, El Atifi M, Gicquel C, Bertagna X, Chambaz E M, Feige J J. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations.  J Clin Endocrinol Metab. 2000;  85 4734-4741
  CrossrefPubMedGoogle Scholar
• 50 Kang D H, Anderson S, Kim Y G et al.. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.  Am J Kidney Dis. 2001;  37 601-611
  PubMedGoogle Scholar
• 51 Kang D H, Joly A H, Oh S W et al.. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1.  J Am Soc Nephrol. 2001;  12 1434-1447
  PubMedGoogle Scholar
• 52 Tanaka K, Sonoo H, Kurebayashi J et al.. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.  Clin Cancer Res. 2002;  8 1125-1131
  PubMedGoogle Scholar
• 53 Tan X J, Lang J H, Liu D Y, Shen K, Leng J H, Zhu L. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis.  Fertil Steril. 2002;  78 148-153
  CrossrefPubMedGoogle Scholar
• 54 Dameron K M, Volpert O V, Tainsky M A, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.  Science. 1994;  265 1582-1584
  CrossrefPubMedGoogle Scholar
• 55 Kieser A, Weich H A, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.  Oncogene. 1994;  9 963-969
  PubMedGoogle Scholar
• 56 Mukhopadhyay D, Tsiokas L, Sukhatme V P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.  Cancer Res. 1995;  55 6161-6165
  PubMedGoogle Scholar
• 57 Grossfeld G D, Ginsberg D A, Stein J P et al.. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.  J Natl Cancer Inst. 1997;  89 219-227
  CrossrefPubMedGoogle Scholar
• 58 Fontanini G, Boldrini L, Calcinai A et al.. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.  Clin Cancer Res. 1999;  5 155-161
  PubMedGoogle Scholar
• 59 Kwak C, Jin R J, Lee C, Park M S, Lee S E. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.  BJU Int. 2002;  89 303-309
  CrossrefPubMedGoogle Scholar
• 60 Chen H, Herndon M E, Lawler J. The cell biology of thrombospondin-1.  Matrix Biol. 2000;  19 597-614
  CrossrefPubMedGoogle Scholar
• 61 Dumont N, Arteaga C L. Transforming growth factor-beta and breast cancer: tumor promoting effects of transforming growth factor-beta.  Breast Cancer Res. 2000;  2 125-132
  CrossrefPubMedGoogle Scholar
• 62 Murphy-Ullrich J E, Schultz-Cherry S, Hook M. Transforming growth factor-beta complexes with thrombospondin.  Mol Biol Cell. 1992;  3 181-188
  PubMedGoogle Scholar
• 63 Taraboletti G, Belotti D, Borsotti P et al.. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor.  Cell Growth Differ. 1997;  8 471-479
  PubMedGoogle Scholar
• 64 Majack R A, Goodman L V, Dixit V M. Cell surface thrombospondin is functionally essential for vascular smooth muscle cell proliferation.  J Cell Biol. 1988;  106 415-422
  CrossrefPubMedGoogle Scholar
• 65 Hogg P J, Hotchkiss K A, Jimenez B M, Stathakis P, Chesterman C N. Interaction of platelet-derived growth factor with thrombospondin 1.  Biochem J. 1997;  326(pt 3) 709-716
  CrossrefPubMedGoogle Scholar
• 66 Krishnaswami S, Ly Q P, Rothman V L, Tuszynski G P. Thrombospondin-1 promotes proliferative healing through stabilization of PDGF.  J Surg Res. 2002;  107 124-130
  PubMedGoogle Scholar
• 67 Ichii T, Koyama H, Tanaka S et al.. Thrombospondin-1 mediates smooth muscle cell proliferation induced by interaction with human platelets.  Arterioscler Thromb Vasc Biol. 2002;  22 1286-1292
  PubMedGoogle Scholar
• 68 Lamszus K, Joseph A, Jin L et al.. Scatter factor binds to thrombospondin and other extracellular matrix components.  Am J Pathol. 1996;  149 805-819
  PubMedGoogle Scholar
• 69 Goicoechea S, Orr A W, Pallero M A, Eggleton P, Murphy-Ullrich J E. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin.  J Biol Chem. 2000;  275 36358-36368
  CrossrefPubMedGoogle Scholar
• 70 Goicoechea S, Pallero M A, Eggleton P, Michalak M, Murphy-Ullrich J E. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin.  J Biol Chem. 2002;  277 37219-37228
  CrossrefPubMedGoogle Scholar
• 71 Wong S Y, Purdie A T, Han P. Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study.  Am J Pathol. 1992;  140 1473-1482
  PubMedGoogle Scholar
• 72 Wakiyama T, Shinohara T, Shirakusa T, John A S, Tuszynski G P. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.  Histol Histopathol. 2001;  16 345-351
  PubMedGoogle Scholar
• 73 Rice A J, Steward M A, Quinn C M. Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast.  J Clin Pathol. 2002;  55 921-925
  CrossrefPubMedGoogle Scholar
• 74 Alvarez A A, Axelrod J R, Whitaker R S et al.. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.  Gynecol Oncol. 2001;  82 273-278
  CrossrefPubMedGoogle Scholar
• 75 Tuszynski G P, Rothman V L, Deutch A H, Hamilton B K, Eyal J. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins.  J Cell Biol. 1992;  116 209-217
  CrossrefPubMedGoogle Scholar
• 76 Tuszynski G P, Rothman V L, Papale M, Hamilton B K, Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.  J Cell Biol. 1993;  120 513-521
  CrossrefPubMedGoogle Scholar
• 77 Bogdanov Jr A, Marecos E, Cheng H C et al.. Treatment of experimental brain tumors with trombospondin-1 derived peptides: an in vivo imaging study.  Neoplasia. 1999;  1 438-445
  CrossrefPubMedGoogle Scholar

George P TuszynskiPh.D. 

Center for Neurovirology and Cancer Biology, Temple University

1900 North 12th Street, Philadelphia, PA 19122

Email: gpt@temple.edu